New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response

Key Points

• Measurable residual disease assessment improves treatment response monitoring in multiple myeloma.
• Next-generation sequencing shows a significant reduction in residual disease in 75 patients after therapy.
• Assessment using a combination of mass spectrometry and next-generation flow cytometry enhances detection sensitivity.
• These innovative methods may enable accurate tracking of disease status during treatment, informing clinical decisions.